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Hyperphosphataemia is associated with increased all-cause mortality in
patients with chronic kidney disease (CKD), but serum phosphate (P) levels
can be managed by dialysis, diet and the use of P binders. Serum P data
were obtained retrospectively from a US dialysis provider for the 9 months
following initiation of haemodialysis (HD) in CKD patients, who were then
grouped according to the variations in their serum P. Group baseline
characteristics and changes in P binder use over time were described.
Variations in average monthly serum P values from months 4 to 9 were
classiﬁed as either consistently in the target range (CT, 3.5–5.5 mg/dL),
consistently low (CL, o 3.5 mg/dL), consistently high (CH, 4 5.5 mg/dL),
or varying between the low and target (LT), target and high (TH) or the low
and high ranges (LH). For each group, baseline characteristics and changes
in P binder use during the study were compared with CT (the reference
group) to identify differences.
In total, 47742 eligible patients were allocated to the six groups: CT,
7301; CL, 131; CH, 5001; LT, 6469; TH, 24469; LH, 4371. CH, TH, and LH
were signiﬁcantly younger than CT, with fewer comorbidities, higher
incidence of elevated parathyroid hormone (PTH) and higher mean serum
P; CH and TH also had higher levels of P binder use. CL and LT were older,
with more comorbidities, lower PTH levels and lower levels of P binder use
than CT. Overall, comparing months 8–9 with baseline (months 1–3), more
patients received P binder therapy (51.7 vs 35.0%), on a larger percentage of
days (50.0 vs 30.9%), but with little change in mean serum P (5.3 vs 5.2 mg/
dL). By group, mean serum P increased numerically in CH (7.5 vs 6.6 mg/
dL) and TH (5.6 vs 5.4 mg/dL) but decreased in other groups.
Serum P can be difﬁcult to control following initiation of HD. Patients
with elevated serum P were younger, and most had higher P binder use
than the reference group. Overall, binder use was lower than in other
studies of HD patients. Dietary education and higher doses of the most
effective P binders may be needed to improve P management.
http://dx.doi.org/10.1016/j.krcp.2012.04.622
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Patients with chronic kidney disease undergoing haemodialysis have a
maximum recommended dietary phosphate (P) intake of 1000 mg/day and
a recommended protein intake of 1.2 g/kg/day. Achieving this level of
protein intake is associated with the best patient outcomes. However,
protein-containing foods also contain P, and elevated serum P is associated
with increased all-cause mortality. It is therefore important to manage the
levels of serum P while maintaining adequate levels of nutrition.
For different P binders, we estimated the dose and associated tablet
burden needed to remove excess P based on the maximum recommended
daily P intake. We also examined the implications for patient nutrition.
Published binding capacities of different P binders in healthy volunteers
ingesting up to 2000 mg/day P, are in the range of 26–135 mg P/g binder.
Assuming that 60% of ingested P is absorbed, and that haemodialysis three-
times weekly will remove 2400 mg P, a haemodialysis patient ingesting
1000 mg/day P will have a residual P burden of 257 mg/day. To bind this,
patients would require a maximum of 3 x 1000 mg lanthanum carbonate
tablets, or approximately 9 x 400 mg calcium carbonate tablets, or
approximately 9 x 800 mg sevelamer hydrochloride tablets.
The recommended protein intake for a 70 kg haemodialysis patient is
84 g/day. A realistic estimate of the average P content of a typical diet is
15 mg/g protein, which equates to a P intake of 1260 mg/day. This is
considerably in excess of the recommended limit and, depending on
vitamin D status more than 60% may be absorbed, further adding to the
residual P burden.
The availability of binding capacity data for P binders, presents
physicians with the possibility of tailoring doses of binder to a patient’s
diet, facilitating sufﬁcient intake of dietary protein while maintaining a
neutral P balance. Use of high-capacity binders, such as lanthanum
carbonate, would minimize the tablet burden faced by patients and this
may also encourage adherence.
http://dx.doi.org/10.1016/j.krcp.2012.04.623
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Hypertriglyceridemia is a comorbidity of chronic kidney disease (CKD)
that contributes to insulin resistance and dysfunctional protein
metabolism in skeletal muscle, resulting in debilitating muscle atrophy.
The saturated fatty acid palmitate (PA) induces muscle insulin resistance
and promotes apoptosis and atrophic signaling pathways. In contrast,
omega-3 polyunsaturated fatty acids like docosahexaenoic acid (DHA)
improve insulin sensitivity and may attenuate activation of pathways that
lead to muscle atrophy. The purpose of this study was to examine the
effects of saturated and omega-3 fatty acids on atrophy-related signaling
pathways in skeletal muscle cells. Our hypothesis was that DHA prevents
the detrimental effects of PA. C2C12 myotubes were treated with 0.1mM
DHA and/or 0.5mM PA for 48 h. Insulin (100nM; 15 min) was added to cells
to activate signaling pathways. The expression of proteins involved in
atrophic and apoptotic signaling pathways was examined by Western
analysis. PA reduced myotube size and number. PA also reduced insulin-
stimulated Akt and Foxo3a phosphorylation plus induced caspase-3 and
actin-fragmentation. All of these responses were blocked by the addition of
DHA; DHA alone had minimal effects on these pathways. In conclusion,
these data suggest that DHA protects muscle cells from activation of
atrophic signaling pathways by high levels of saturated fatty acids.
Therefore, protein-energy wasting during CKD may be improved by DHA
supplements.Support: NIH DK007734
http://dx.doi.org/10.1016/j.krcp.2012.04.624
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Muscle atrophy is prevalent in chronic kidney disease (CKD) patients.
MicroRNAs play a critical role in biological processes including muscle
atrophy. MicroRNA-23a (miR-23a) negatively regulates the expression of
two atrophy-related ubiquitin ligases, atrogin-1 and MuRF1; it is reduced
in muscle during atrophy. Although miR-23a expression was recently
shown to be positively regulated by NFATc3, the underlying mechanism of
miR-23a suppression during atrophy remains unknown. We previously
reported that the activity of calcineurin (Cn), the calcium-activated
phosphatase that regulates NFATc proteins, is decreased when insulin
signaling is decreased. Since CKD causes muscle atrophy, and
glucocorticoids are required for the response, we investigated how
dexamethasone (DEX) affects Cn activity, NFATc3 signaling, and miR-23a
expression. C2C12 or L6 myotubes were treated with 100 uM DEX to
induce atrophy. Within 1 h, Cn activity was reduced and less NFATc3 was
located in the nucleus. Further, miR-23a was also decreased within 30
minutes. After 48 h, expression of the NFATC3 target gene, MCIP1.4, and
miR-23a were decreased. Expression of atrogin-1 and MuRF1 were also
increased 48 h after DEX. Collectively, these ﬁndings indicate the Cn-NFAT
signaling pathway may play an important role in the regulation of atrogin-
1 and MuRF1 by suppressing miR23a during CKD and glucocorticoid-
related muscle atrophy. Support: NIH DK007656; AHA GRNT7660020
http://dx.doi.org/10.1016/j.krcp.2012.04.625
Kidney Res Clin Pract 31 (2012) A16–A96A92
